Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578


News SummaryMost relevantAll newsSector newsTweets 

SANOFI : EMA Recommends Approval Of Sanofi Pediatric Vaccine Hexyon/Hexacima 6-in-1

share with twitter share with LinkedIn share with facebook
share via e-mail
02/22/2013 | 01:58pm CEST

PARIS--The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recommended market approval for Sanofi Pasteur's 6-in-1 pediatric vaccine, French drugs giant Sanofi (>> SANOFI) said Friday.


- Hexyon/Hexacima is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.

- The new vaccine will be commercialized under the brand name Hexyon in Western European countries by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima in Eastern European countries by Sanofi Pasteur.

- The vaccine "reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases," said Olivier Charmeil, President and CEO of Sanofi Pasteur.

-Hexyon/Hexacima would be indicated for primary and booster vaccination of infants from six weeks of age in accordance with official recommendations.

- The CHMP positive opinion is supported by results of multi-center clinical studies involving approximately 5,000 infants; phase III clinical studies comparing Hexyon/Hexacima to licensed combination vaccines demonstrated that HexyonTM/HexacimaTM is safe and induces a robust immune response against all six targeted diseases.

-Write to Mimosa Spencer at mimosa.spencer@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
03:13a SANOFI : Ionis subsidiary Akcea files for $100 million stock offering
03/27 SANOFI : Disclosure of trading in own shares
03/27 VIVUS,INC. (NASDAQ : VVUS) Files An 8-K Entry into a Material Definitive Agreeme..
03/26 SANOFI INDIA : Quarterly results - sanofi india limited
03/24 SANOFI : U.S. Patents Awarded to Inventors in Massachusetts (March 24)
03/24 WHAT MIGHT SANOFI SA (ADR) (NYSE : SNY) Mean For Flexion Therapeutics (NASDAQ:FL..
03/24 FLEXION THERAPEUTICS : Burlington biotech Flexion could be sold to Sanofi
03/23 SANOFI : Findings from Sanofi Provides New Data about Adeno-Associated Virus (Ch..
03/23 SANOFI : $401,250 Federal Contract Awarded to Sanofi Pasteur
03/22 SANOFI : Genzyme Extends its Multiple Myeloma Journey Partners Program to Cities..
More news
Sector news : Pharmaceuticals - NEC
08:48aDJDuPont, Dow Get EU Approval for Merger -- WSJ
03/27DJALEXION PHARMACEUTICALS : Names New CEO Following Internal Sales-Practice Probe
03/27DJEU Clears Dow-DuPont Deal With Conditions -- 2nd Update
03/27DJEU Clears Dow-DuPont Deal With Conditions -- Update
03/27 Chinese drug approval boosts AstraZeneca's lung cancer hopes
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03/27 My Favorite Biotech Takeover Play
03/27 Sanofi gives up on ED med Stendra, returns rights to VIVUS
03/26 FOCUS ON EUROPE : Who Earned A $250M Performance Bonus Last Week?
03/24 Industry And Dark Pool Traders Bearish On Amgen
03/24 FDA Decision For Dupixent As Novartis Drives Its CAR-T
Financials (€)
Sales 2017 36 498 M
EBIT 2017 9 302 M
Net income 2017 5 592 M
Debt 2017 4 507 M
Yield 2017 3,65%
P/E ratio 2017 18,39
P/E ratio 2018 17,38
EV / Sales 2017 3,08x
EV / Sales 2018 2,94x
Capitalization 107 845 M
More Financials
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 82,2 €
Spread / Average Target -1,6%
Consensus details
EPS Revisions
More Estimates Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI7.76%117 163
JOHNSON & JOHNSON8.91%341 030
ROCHE HOLDING LTD.8.73%220 248
PFIZER INC.5.23%203 546
NOVARTIS AG-0.47%195 735
MERCK & CO., INC.7.34%173 493
More Results